共 24 条
[1]
肝衰竭诊治指南(2018年版).[J]..临床肝胆病杂志.2019, 01
[2]
Targeted and Immune-based Therapies for Hepatocellular Carcinoma.[J].Tim F. Greten;Chunwei Walter Lai;Guangfu Li;Kevin F. Staveley-O’Carroll.Gastroenterology.2018, 2
[3]
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.[J].Anastasia Constantinidou;Constantinos Alifieris;Dimitrios T. Trafalis.Pharmacology and Therapeutics.2018,
[4]
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.[J].Xiao-xiao He;Liang-liang Shi;Meng-jun Qiu;Qiu-ting Li;Meng-meng Wang;Zhi-fan Xiong;Sheng-li Yang.Biochemical and Biophysical Research Communicatio.2018,
[5]
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
[J].
LANCET ONCOLOGY,
2018, 19 (07)
:940-952
Zhu, Andrew X.
;
Finn, Richard S.
;
Edeline, Julien
;
Cattan, Stephane
;
Ogasawara, Sadahisa
;
Palmer, Daniel
;
Verslype, Chris
;
Zagonel, Vittorina
;
Fartoux, Laetitia
;
Vogel, Arndt
;
Sarker, Debashis
;
Verset, Gontran
;
Chan, Stephen L.
;
Knox, Jennifer
;
Daniele, Bruno
;
Webber, Andrea L.
;
Ebbinghaus, Scot W.
;
Ma, Junshui
;
Siegel, Abby B.
;
Cheng, Ann-Lii
;
Kudo, Masatoshi
.
[6]
Targeting the microenvironment in solid tumors.[J].Carmen Belli;Dario Trapani;Giulia Viale;Paolo D'Amico;Bruno Achutti Duso;Paolo Della Vigna;Franco Orsi;Giuseppe Curigliano.Cancer Treatment Reviews.2018,
[7]
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.[J].Masatoshi Kudo;Richard S Finn;Shukui Qin;Kwang-Hyub Han;Kenji Ikeda;Fabio Piscaglia;Ari Baron;Joong-Won Park;Guohong Han;Jacek Jassem;Jean Frederic Blanc;Arndt Vogel;Dmitry Komov;T R Jeffry Evans;Carlos Lopez;Corina Dutcus;Matthew Guo;Kenichi Saito;Silvija Kraljevic;Toshiyuki Tamai;Min Ren;Ann-Lii Cheng.The Lancet.2018, 1012
[8]
Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
[J].
SEMINARS IN ONCOLOGY,
2019, 46 (01)
:57-64
Cabanillas, Maria E.
;
Takahashi, Shunji
.
[9]
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
[J].
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,
2019, 1871 (02)
:199-224
Wang, Manni
;
Liu, Yu
;
Cheng, Yuan
;
Wei, Yuquan
;
Wei, Xiawei
.
[10]
Biomarkers of response to PD-1/PD-L1 inhibition.[J].Saman Maleki Vareki;Carmen Garrigós;Ignacio Duran.Critical Reviews in Oncology / Hematology.2017,